Scorpius Holdings Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Scorpius Holdings kazanç ve gelirinin sırasıyla yıllık 75.2% ve 50.1% oranında artması tahmin edilirken, EPS'nin yıllık 98.3% oranında büyümesi bekleniyor.

Anahtar bilgiler

75.2%

Kazanç büyüme oranı

98.3%

EPS büyüme oranı

Biotechs kazanç büyümesi	28.3%
Gelir büyüme oranı	50.1%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	30 Sep 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Here's Why We're Watching Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Dec 28

Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Sep 02

Reflecting on Heat Biologics' (NASDAQ:HTBX) Share Price Returns Over The Last Five Years

Mar 07

Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Jan 13

Kazanç ve Gelir Büyüme Tahminleri

NYSEAM:SCPX - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2025	16	-9	N/A	N/A	1
12/31/2024	8	-22	N/A	N/A	1
9/30/2024	10	-30	-22	-22	N/A
6/30/2024	10	-30	-21	-21	N/A
3/31/2024	10	-32	-22	-22	N/A
12/31/2023	7	-40	-34	-32	N/A
9/30/2023	2	-51	-41	-38	N/A
6/30/2023	2	-50	-44	-26	N/A
3/31/2023	1	-45	-30	-9	N/A
12/31/2022	0	-41	-26	-6	N/A
9/30/2022	1	-38	-29	-9	N/A
6/30/2022	1	-36	-30	-29	N/A
3/31/2022	2	-36	-46	-43	N/A
12/31/2021	2	-35	-40	-38	N/A
9/30/2021	2	-28	-35	-33	N/A
6/30/2021	2	-29	-27	-23	N/A
3/31/2021	3	-27	-22	-21	N/A
12/31/2020	3	-26	-22	-22	N/A
9/30/2020	4	-23	-16	-16	N/A
6/30/2020	4	-20	-15	-15	N/A
3/31/2020	3	-21	-15	-14	N/A
12/31/2019	3	-20	-13	-13	N/A
9/30/2019	3	-22	-19	-19	N/A
6/30/2019	5	-19	-18	-18	N/A
3/31/2019	6	-18	-22	-22	N/A
12/31/2018	6	-16	-22	-22	N/A
9/30/2018	4	-14	-13	-13	N/A
6/30/2018	3	-13	N/A	-13	N/A
3/31/2018	2	-12	N/A	-7	N/A
12/31/2017	2	-12	N/A	-6	N/A
9/30/2017	1	-12	N/A	-12	N/A
6/30/2017	1	-11	N/A	-10	N/A
3/31/2017	0	-11	N/A	-12	N/A
12/31/2016	0	-13	N/A	-14	N/A
9/30/2016	0	-16	N/A	-16	N/A
6/30/2016	N/A	-19	N/A	-18	N/A
3/31/2016	N/A	-21	N/A	-18	N/A
12/31/2015	N/A	-20	N/A	-17	N/A
9/30/2015	N/A	-17	N/A	-15	N/A
6/30/2015	N/A	-15	N/A	-14	N/A
3/31/2015	N/A	-13	N/A	-12	N/A
12/31/2014	N/A	-12	N/A	-10	N/A
9/30/2014	N/A	-10	N/A	-9	N/A
6/30/2014	N/A	-10	N/A	-9	N/A
3/31/2014	N/A	-8	N/A	-8	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: SCPX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: SCPX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: SCPX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: SCPX şirketinin gelirinin (yıllık 50.1% ) US pazarından (yıllık 8.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: SCPX şirketinin gelirinin (yıllık 50.1% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: SCPX 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Scorpius Holdings Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Scorpius Holdings, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023

Price target decreased by 9.1% to US$10.00

Price target decreased to US$21.83

Price target decreased to US$23.83

Consensus forecasts updated

Consensus forecasts updated

Recent updates

Scorpius Holdings, Inc. announced delayed 10-Q filing

Scorpius Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $12.5 million.

NYSE American Withdraws Delisting Determination of Scorpius Holdings Common Stock

Scorpius Holdings Set to Launch First Mammalian Cgmp Campaign At San Antonio Facility in the 2024 3Rd Quarter

Scorpius Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $12.5 million.

Scorpius Holdings, Inc Successfully Executes First cGMP Microbial Batches at San Antonio Facility

NYSE Determines to Commence Proceedings to Delist Scorpius Holdings' Common Stock from the NYSE American Due to Company No Longer Suitable for Listing Pursuant to Section 1003(f)(v) of the NYSE American Company Guide

Scorpius Holdings, Inc., Annual General Meeting, Jul 19, 2024

Scorpius Holdings, Inc., Annual General Meeting, Aug 02, 2024

Scorpius Holdings, Inc. Provides Non-Compliance Update

Scorpius Holdings, Inc. announced delayed 10-Q filing

Scorpius Holdings, Inc. has completed a Composite Units Offering in the amount of $6 million.

Scorpius Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $11.5 million.

Scorpius Holdings, Inc. announced that it expects to receive $0.75 million in funding from Elusys Holdings Inc.

Scorpius Holdings Regains Compliance with Section 1007 of the NYSE American Company Guide

Scorpius Holdings Announces Receipt of Filing Delinquency Notification

Scorpius Holdings, Inc. announced delayed annual 10-K filing

Scorpius Holdings, Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

Scorpius Holdings, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023

Price target decreased by 9.1% to US$10.00

Nighthawk Biosciences, Inc. Announces the Promotion of Joe Payne to President and Chief Operating Officer of Its Scorpius Biomanufacturing Subsidiary

NightHawk Biosciences, Inc. Announces Executive Appointments

Jeffrey Wolf acquired Elusys Therapeutics, Inc. from NightHawk Biosciences, Inc. (NYSEAM:NHWK).

NightHawk Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $4.037193 million.

NightHawk Biosciences, Inc. announced that it expects to receive $2.25 million in funding

NightHawk Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $4.037193 million.

NightHawk Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $4.037193 million.

NightHawk Biosciences, Inc. announced delayed 10-Q filing

NightHawk Biosciences, Inc., Annual General Meeting, Sep 27, 2023

NightHawk Biosciences, Inc., Annual General Meeting, Sep 15, 2022

Richard Myers to Become Chairman of NightHawk's BioThreat Advisory Board

Heat Biologics to Voluntarily Withdraw the Listing of the Company’s Common Stock

Heat Biologics Announces New PTX-35 Preclinical Data in Organ Transplantation and Provides Update on HS-110

Here's Why We're Watching Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Heat Biologics, Inc. (NasdaqCM:HTBX) executed a definitive merger agreement to acquire Elusys Therapeutics, Inc.

Heat Biologics Unveils RapidVax, A Novel Cellular Vaccine Platform Targeting Known and Unknown Emerging Biological Threats

Third quarter 2021 earnings released: US$0.30 loss per share (vs US$0.43 loss in 3Q 2020)

Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Heat Biologics Unveils Skunkworx Bio, New Drug Discovery Subsidiary

Price target decreased to US$21.83

Price target decreased to US$23.83

Second quarter 2021 earnings released: US$0.26 loss per share (vs US$0.35 loss in 2Q 2020)

Consensus forecasts updated

Heat Biologics to Showcase Favorable Survival Data of HS-110 in Previously Treated Non-Small Cell Lung Cancer Patients

Heat Biologics, Inc. Announces Promising Survival Data of HS-110 in Two Treatment Settings of Lung Cancer for Presentation at 2021 American Society of Clinical Oncology Annual Meeting

Independent Lead Director recently sold US$205k worth of stock

Consensus forecasts updated

Consensus revenue estimates fall to US$1.98m

Heat Biologics names Anthony Manning as chief scientific advisor

Price target decreased to US$24.67

First quarter 2021 earnings released: US$0.31 loss per share (vs US$0.77 loss in 1Q 2020)

Heat Biologics EPS misses by $0.01, misses on revenue

We're Hopeful That Heat Biologics (NASDAQ:HTBX) Will Use Its Cash Wisely

Full year 2020 earnings released: US$1.63 loss per share (vs US$4.21 loss in FY 2019)

Reflecting on Heat Biologics' (NASDAQ:HTBX) Share Price Returns Over The Last Five Years

Heat Biologics, Inc. Announces Positive Interim Survival Data from Ongoing HS-110 Phase 2 Non-Small Cell Lung Cancer Trial

Heat Biologics, Inc. Announces Publication of Additional Preclinical COVID-19 Vaccine Results

New 90-day high: US$8.76

Price target lowered to US$27.30

Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Heat Biologics, Inc. Announces the Promotion of William Ostrander to Chief Financial Officer

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin